Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway

Liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death. Most (75–85%) primary liver cancers occurring worldwide are hepatocellular carcinoma (HCC). The development of resistance and other drug related side effects are the prime reasons for the failure o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xue, Jiao, Fangzhou, Zhang, Lan, Jiang, Yingan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117156/
https://www.ncbi.nlm.nih.gov/pubmed/33995073
http://dx.doi.org/10.3389/fphar.2021.654986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117156/
https://www.ncbi.nlm.nih.gov/pubmed/33995073
http://dx.doi.org/10.3389/fphar.2021.654986

Ejemplares similares